The FDA Approval of Regeneron’s/Sanofi’s Praluent Is A Big Deal. Will the FDA Approve Nabriva Therapeutics’ Antibiotic Contepo Today?

FDA Approval of Regeneron's/Sanofi's Praluent
Will Nabriva's Antibiotic Product Contepo Also Get FDA Approval?
Praluent's Approval Is a Big Deal
The approval of Regeneron’s (REGN) and Sanofi’s (SNY) supplemental biological license application (sBLA) aimed at updating Praluent’s (alirocumab) prescribing information is, indeed, a big deal. Proven life-saving benefits are confirmed. Comprising reducing the overall risk of major adverse . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.